Novadip Biosciences, a Belgium-based biopharmaceutical company, has raised an additional €40 million in a Series B equity round and non-dilutive funding.
Novadip Biosciences, a Belgium-based biopharmaceutical company, has raised an additional €40 million in a Series B equity round and non-dilutive funding.